Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)

다국어 초록 (Multilingual Abstract)

Hunter syndrome (or mucopolysaccharidosis type II [MPS II]) arises because of a deficiency in the lysosomal enzyme iduronate-2-sulfatase. Short stature is a prominent and consistent feature in MPS II. Enzyme replacement therapy (ERT) with idursulfase (Elaprase®) or idursulfase beta (Hunterase®) have been developed for these patients. The effect of ERT on the growth of Korean patients with Hunter syndrome was evaluated at a single center. This study comprised 32 patients, who had received ERT for at least 2 yr; they were divided into three groups according to their ages at the start of ERT: group 1 (<6 yr, n=14), group 2 (6-10 yr, n=11), and group 3 (10-20 yr, n=7). The patients showed marked growth retardation as they got older. ERT may have less effect on the growth of patients with the severe form of Hunter syndrome. The height z-scores in groups 2 and 3 revealed a significant change (the estimated slopes before and after the treatment were -0.047 and -0.007, respectively: difference in the slope, 0.04; P<0.001). Growth in response to ERT could be an important treatment outcome or an endpoint for future studies.

참고문헌 (Reference)

1 Neufeld E, "The mucopolysaccharidoses" McGraw-Hill 3421-3452, 2001

2 Poorthuis BJ, "The frequency of lysosomal storage diseases in The Netherlands" 105 : 151-156, 1999

3 Jones SA, "The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS)" 109 : 41-48, 2013

4 Gordon M, "Psychosocial aspects of constitutional short stature: social competence, behavior problems, self-esteem, and family functioning" 101 : 477-480, 1982

5 Sohn YB, "Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome)" 8 : 42-, 2013

6 Muenzer J, "Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome" 13 : 95-101, 2011

7 Wraith JE, "Initial report from the Hunter Outcome Survey" 10 : 508-516, 2008

8 Lin HY, "Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004" 149A : 2009

9 Kim J, "IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome" 68 : 796-802, 2013

10 Sohn YB, "Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type II" 81 : 185-190, 2012

11 Stephen MD, "Health-related quality of life and cognitive functioning in pediatric short stature: comparison of growth-hormone-naïve, growth-hormone-treated, and healthy samples" 170 : 351-358, 2011

12 Rozdzynska A, "Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II" 100 : 456-460, 2011

13 Schulze-Frenking G, "Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II" 34 : 203-208, 2011

14 Baehner F, "Cumulative incidence rates of the mucopolysaccharidoses in Germany" 28 : 1011-1017, 2005

15 Stabler B, "Academic achievement and psychological adjustment in short children : the National Cooperative Growth Study" 15 : 1-6, 1994

16 Ok Jeong Lee, "A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients" 대한소아과학회 55 (55): 88-92, 2012

17 Muenzer J, "A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)" 8 : 465-473, 2006

18 Schwartz IV, "A clinical study of 77 patients with mucopolysaccharidosis type II" 96 : 63-70, 2007